Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Published Time:
2025-01-22 17:49
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
Dr. Gong Yanchun, Co-founder and CEO, stated: "Jiangsu Vcare has always adhered to the strategic layout of dual-wheel drive and coordinated development of its two core businesses: independent research and development of innovative drugs, and full-industry-chain CRO/CDMO services for pharmaceuticals.Three self-developed drug candidates have now entered confirmatory clinical studies, while our CRO/CDMO business continues rapid expansion with increasingly diversified service models. Our forward-looking strategic planning positions us to further solidify core competitiveness. With strong support from investors , we will break new ground, navigate market cycles, and achieve sustainable high-quality development."
Previous Page
Related News
16
2021
/
08
Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
View Details
29
2021
/
07
Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) secures another strategic investment of CNY 100 million. This round was jointly invested by Nanjing NII Group, Renpu Capital, and Nanjing Innovation Capital Group. The funds will primarily be used to advance the clinical research of innovative drug pipeline projects like Vicagrel and VC004, while accelerating strategic layout in the CDMO business sector.
View Details
24
2021
/
06
Vcare Pharmatech Selected as 2021 Nanjing Nurtured Unicorn Enterprise
On June 23, 2021, the list of Nanjing Unicorn and Gazelle Enterprises was announced. Jiangsu Vcare Pharmatech Technology Co., Ltd.(Vcare Pharmatech) was selected as a 2021 Nanjing Nurtured Unicorn Enterprise.
View Details
22
2021
/
03
Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.
View Details
12
2021
/
03
Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
View Details
08
2021
/
03
Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn